Beiley Biofund

Beiley Biofund Net Debt/Equity

The Net Debt to Equity Ratio of Beiley Biofund (7882.TWO) as of Nov 9, 2026 is -0.59. In the previous year, Net Debt to Equity Ratio was -0.75 — a change of -21.39% (higher).

Net Debt/Equity

-0.59

YoY

-21.39%

Last updated:

Net Debt to Equity Ratio of Beiley Biofund is 2024 -0.59 . Net Debt to Equity Ratio of Beiley Biofund was 2023 -0.75 . It decreases by -21.39% higher compared to the previous year.

The Beiley Biofund Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2023
-0.75 TWD
Jan 1, 2024
-0.59 TWD
The Beiley Biofund Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.59-21.39%
-0.75—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beiley Biofund Stock analysis

What does Beiley Biofund do? Beiley Biofund Inc generates revenue through venture capital investments in biotechnology and healthcare sectors. The company focuses on new drug and pharmaceutical R&D, advanced medical devices, pharmaceutical manufacturing, diagnostics, precision medicine, innovative medical service technologies, healthcare networks, and agricultural biotechnology. Its primary investment scope is domestic, targeting companies within Taiwan's biotech industry. The firm's revenue comes from capital gains and returns on its portfolio investments in these specialized areas. Beiley Biofund Inc operates as a Taiwan-based venture capital firm with a domestic investment focus. It targets biotechnology and healthcare companies developing innovative solutions in drug development, medical devices, and precision medicine. The firm's investment strategy centers on companies within Taiwan's biotech ecosystem, providing capital for growth and innovation. Revenue is derived from successful exits and equity appreciation in its portfolio companies. The company's investment areas include pharmaceutical manufacturing and services, diagnostics, precision medicine, and agricultural biotechnology. Beiley Biofund Inc concentrates on firms within Taiwan's domestic market, making capital available for biotech startups and established players. Revenue is generated through the financial performance of its investment portfolio in these specific sectors. Beiley Biofund is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beiley Biofund stock

Net Debt to Equity Ratio of Beiley Biofund is -0.59 in 2024.

Net Debt to Equity Ratio of Beiley Biofund changed from -0.75 to -0.59, representing a -21.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Beiley Biofund since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Beiley Biofund with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Beiley Biofund

All Key Metrics — Beiley Biofund